Ac-RYYRWK-NH2 TFA
Need Assistance?
  • US & Canada:
    +1-844-BOC(262)-0123
  • UK: +44-20-3286-1088

Ac-RYYRWK-NH2 TFA

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP).

Category
Peptide Inhibitors
Catalog number
BAT-016410
CAS number
408305-09-9
Molecular Formula
C51H70F3N15O11
Molecular Weight
1126.19
Ac-RYYRWK-NH2 TFA
IUPAC Name
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanamide;2,2,2-trifluoroacetic acid
Synonyms
Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-NH2.TFA; N-acetyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-arginyl-L-tryptophyl-L-lysinamide trifluoroacetic acid; L-Lysinamide, N2-acetyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-arginyl-L-tryptophyl-, mono(trifluoroacetate) (salt)
Related CAS
200959-47-3 (free base) 2863657-54-7 (acetate salt)
Purity
≥95%
Sequence
Ac-RYYRWK-NH2.TFA
Storage
Store at -20°C
InChI
InChI=1S/C49H69N15O9.C2HF3O2/c1-28(65)59-37(11-6-22-56-48(52)53)43(69)62-40(25-30-15-19-33(67)20-16-30)46(72)63-39(24-29-13-17-32(66)18-14-29)45(71)61-38(12-7-23-57-49(54)55)44(70)64-41(26-31-27-58-35-9-3-2-8-34(31)35)47(73)60-36(42(51)68)10-4-5-21-50;3-2(4,5)1(6)7/h2-3,8-9,13-20,27,36-41,58,66-67H,4-7,10-12,21-26,50H2,1H3,(H2,51,68)(H,59,65)(H,60,73)(H,61,71)(H,62,69)(H,63,72)(H,64,70)(H4,52,53,56)(H4,54,55,57);(H,6,7)/t36-,37-,38-,39-,40-,41-;/m0./s1
InChI Key
IIVXGPHKYHMNLB-UCTQLVHTSA-N
Canonical SMILES
CC(=O)NC(CCCN=C(N)N)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CCCCN)C(=O)N.C(=O)(C(F)(F)F)O
Online Inquiry
0
Inquiry Basket

No data available, please add!

Delete selectedGo to checkout

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

x